An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis

Multiple Sclerosis

Volumn 13, Issue 3, 2007, Pages 343-347

  Di Rezze, S ^a   Gupta, S ^b,c   Durastanti, V ^a   Millefiorini, E ^a   Pozzilli, C ^a   Bagnato, Francesca ^a,c,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d NONE   (United States)

Author keywords

Contrast enhancing lesions; Inflammation; Interferon beta; Lesion size; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE OF ONSET; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; TIME FACTORS;

EID: 34248157698     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506071172     Document Type: Article

References (18)

1. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-66.
2. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short-term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996; 61: 251-S8.
3. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-36.
4. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 2005; 62: 785-92.
5. van Waesberghe JH, van Walderveen MA, Castelijins JA, Scheltens P, Lycklama a Nijeholt GJ et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 1998; 19: 675-83.
6. Ciccarelli O, Giugni E, Paolillo A, Mainero C, Gasperini C, Bastianello S et al. Magnetic resonance outcome of new enhancing lesion in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6: 455-59.
7. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
8. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49: 793-96.
9. Hiehle JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995; 16: 69-77.
10. Miller DH, Altmann D, Thompson AJ, Kappos L, Wagner K, Beckmann K. Sample size calculations for a parallel groups, placebo-controlled treatment trial in secondary progressive multiple sclerosis using cerebral atrophy as the primary outcome measure. Neurology 2004; 62: A349.
11. Bagnato F, Gupta S, Ohayon JM, Stone RD, McFarland HF. Sample size estimations for MRI-monitored trials of MS considering reduction in formation of new black holes as primary endpoint. Neurology 2005; 64: A243.
12. Filippi M, Rovaris M, Capra R, Gasperini C, Prandini F, Martinelli V et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999; 67: 386-89.
13. Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57: 2185-90.
14. Gupta S, Solomon JM, Tasciyan TA, Cao, MM, Stone RD, Ostuni JL et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005; 11: 658-68.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
16. Pellegrini P, Totaro R, Contasta I, Berghella AM, Russo T, Carolei A et al. IFNβ-1a treatment and reestablishment of Th1 regulation in MS patients. Dose effects. Clin Neuropharmacol 2004; 27: 258-69.
17. Graber J, Zhan M, Ford D, Kursch F, Francis G, Bever C et al. Interferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005; 161: 169-76.
18. Paul WE. Fundamental immunology, third edition. Raven Press.